Dudediligence.

Immunocore Holdings plc

IMCRNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$80.2MSep ’24$84.1MDec ’24$93.9MMar ’25$98.0MJun ’25$103.7MSep ’25$104.5MDec ’25$106.7MMar ’26$115.9MJun ’26
Net income, by quarter
$8.7MSep ’24−$23.8MDec ’24$5.0MMar ’25−$10.3MJun ’25−$177,000Sep ’25−$30.1MDec ’25$13.0MMar ’26−$808,000Jun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$36.5M$174.4M$249.4M$310.2M$400.0M
Gross profit$36.5M$173.3M$248.4M$307.5M$394.9M
Operating income−$174.6M−$51.7M−$59.6M−$70.5M−$45.4M
Net income−$180.0M−$52.5M−$55.3M−$51.1M−$35.5M
Operating cash flow−$143.1M−$49.2M$2.9M$26.1M−$10.7M
Free cash flow−$144.5M−$51.4M−$2.5M$20.9M−$15.1M
Cash$321.1M$402.5M$442.6M$455.7M$467.7M
Shares outstanding42.5M48.1M49.7M50.1M50.7M